New targeted drug trial offers hope for Tough-to-Treat tumors
NCT ID NCT05745623
Summary
This trial is testing an experimental drug called ICP-723 for people with advanced solid tumors or brain tumors that have specific genetic changes called NTRK fusions. The study aims to see how well the drug shrinks tumors and controls cancer growth in about 70 participants who haven't tried similar targeted treatments before. Researchers will measure tumor response, track side effects, and see how long the treatment keeps the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS HARBORING NTRK FUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Conditions
Explore the condition pages connected to this study.